KIMBERLY PORTCH: Open Payments
NPI 1164058277 · SPOKANE, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,934 in 172 payments from 45 companies in 2025. Trend: 2023 $4,551 · 2024 $3,686 · 2025 $3,934
Food & beverage: $3,854Education: $80
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 25 | $411 |
| Merck Sharp & Dohme LLC | 12 | $322 |
| PFIZER INC. | 13 | $258 |
| AstraZeneca Pharmaceuticals LP | 10 | $248 |
| Janssen Biotech, Inc. | 7 | $242 |
| TerSera Therapeutics LLC | 6 | $195 |
| Exelixis Inc. | 11 | $161 |
| BeOne Medicines USA, Inc. | 6 | $141 |
| Aveo Pharmaceuticals, Inc. | 4 | $135 |
| Regeneron Healthcare Solutions, Inc. | 4 | $124 |
Products named: KEYTRUDA, RYBREVANT, KISQALI, CABOMETYX, SCEMBLIX, BRUKINSA, AYVAKIT, FOTIVDA.
Industry payments across WA — which companies pay providers there.
